Can the pharmaceutical industry reduce attrition rates?

Philip Ma, Rodney Zemmel, Value of novelty Nature Reviews Drug Discovery. ,vol. 1, pp. 571- 572 ,(2002) , 10.1038/NRD884

Bruce Booth, Robert Glassman, Philip Ma, Oncology's trials Nature Reviews Drug Discovery. ,vol. 2, pp. 609- 610 ,(2003) , 10.1038/NRD1158

Simon Frantz, 2003 approvals: a year of innovation and upward trends Nature Reviews Drug Discovery. ,vol. 3, pp. 103- ,(2004) , 10.1038/NRD1327

Francesca Lazner, Maxine Gowen, Ismail Kola, An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling Molecular Medicine Today. ,vol. 5, pp. 413- 414 ,(1999) , 10.1016/S1357-4310(99)01563-4

Maxine Gowen, Francesca Lazner, Robert Dodds, Rasesh Kapadia, John Feild, Michael Tavaria, Ivan Bertoncello, Fred Drake, Silva Zavarselk, Irene Tellis, Paul Hertzog, Christine Debouck, Ismail Kola, Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. Journal of Bone and Mineral Research. ,vol. 14, pp. 1654- 1663 ,(1999) , 10.1359/JBMR.1999.14.10.1654

Joseph A DiMasi, Ronald W Hansen, Henry G Grabowski, The price of innovation: new estimates of drug development costs Journal of Health Economics. ,vol. 22, pp. 151- 185 ,(2003) , 10.1016/S0167-6296(02)00126-1

Steven L Roberds, John Anderson, Guriqbal Basi, Michael J Bienkowski, Daniel G Branstetter, Karen S Chen, Stephen Freedman, Normand L Frigon, Dora Games, Kang Hu, Kelly Johnson-Wood, Karl E Kappenman, Thomas T Kawabe, Ismail Kola, Ralf Kuehn, Michael Lee, Weiqun Liu, Ruth Motter, Nanette F Nichols, Michael Power, David W Robertson, Dale Schenk, Michael Schoor, George M Shopp, Mary E Shuck, Sukanto Sinha, Kjell A Svensson, Gwen Tatsuno, Hartmut Tintrup, John Wijsman, Sarah Wright, Lisa McConlogue, BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer’s disease therapeutics Human Molecular Genetics. ,vol. 10, pp. 1317- 1324 ,(2001) , 10.1093/HMG/10.12.1317